Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listOmarigliptin (MK-3102)

Omarigliptin (MK-3102)

  • CAS NO.:1226781-44-7
  • Empirical Formula: C17H20F2N4O3S
  • Molecular Weight: 398.43
  • MDL number: MFCD22573261
  • EINECS: 682-558-0
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 15:53:33
Omarigliptin (MK-3102) Structural

What is Omarigliptin (MK-3102)?

Description

Merck earned its first global approval for omarigliptin in Japan in 2015, and phase III development is ongoing in other countries around the globe for this interesting small molecule DPP-4 inhibitor. Interestingly, while most DPP-4 inhibitors used to treat type 2 DM require daily administration, omarigliptin is a weekly treatment. The process-scale synthesis of omarigliptin has been nicely described in an October 2015 paper from the Merck process group.

Description

MK-3102 is a potent, reversible, and competitive inhibitor of dipeptidyl peptidase 4 (DPP-4; IC50 = 1.6 nM; Ki = 0.8 nM). It is selective for DPP-4 over 168 proteases, ion channels, and enzymes with IC50 values greater than 10 μM in all assays. MK-3102 significantly reduces blood glucose levels in a dose-dependent manner in vivo in rats. It also has a long half-life (11 and 22 hours in rat and dog, respectively) making it suitable for once weekly dosing. Clinical trials demonstrate that formulations containing MK-3102 reduce plasma glucose and HbA1c in patients with type 2 diabetes mellitus (T2DM).

The Uses of Omarigliptin (MK-3102)

Omarigliptin is a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor to be used as treatment for type 2 diabetes.

Definition

ChEBI: Omarigliptin is a pyrrolopyrazole.

Synthesis

The synthesis began with the efficient condensation of pyrrolidinone 149 with dimethylformamide-dimethylacetal (DMF-DMA) to afford enaminoketone 150 in 88% yield. Subsequent condensation with hydrazine monohydrate gave tertiary alcohol 151 in 92% yield, and this step was followed by acid-promoted dehydration to afford fused pyrazole 152. An initial kinetic mesylation delivered a 1:5 ratio of 147:153, in favor of the undesired regioisomer. However, when the crude mixture was warmed to ambient temperature and treated with potassium tert-butoxide, thermodynamic equilibration provided the more stable N1-mesylate 147. This process furnished the desired regioisomer 147 in a 30:1 ratio and 84% yield over the two steps. Reaction monitoring by HPLC suggests that cleavage of the mesyl group of 153 results in anion formation on the adjacent nitrogen, which then allows for mesylation at the desired position.
Synthesis_1226781-44-7
Ester 154 was subjected to a three-step sequence whereby alkylation with propargyl besylate followed by saponification with sodium hydroxide and Boc protection resulted in amide 155 in 75% yield over three steps. The Weinreb amide was then subjected to the Knochel ?°turbo Grignard?± reagent derived from 1-bromo-2,4-difluorobenzene to provide ketone 156 in 89% yield. An enantioselective transfer hydrogenation was carried out utilizing (R,R)-Ts- DENEB as the chiral induction reagent to afford intermediate 157 in excellent yield and enantio- and diastereoselectivity, which underwent ruthenium-mediated cyclization with the pendant alkyne to afford dihydropyran 158 in 86% yield. A two-step hydroboration/oxidation involving the endocyclic vinyl ether furnished 159 as a mixture of diastereomers in 89% yield, and this was followed by RuCl3/NaBO3-mediated oxidation to provide the lactone fragment 148 in 80% yield.
QQ??í?20210205145459.jpg
Removal of the Boc group within 147 was effected upon treatment with TFA, affording intermediate 160, which was not isolated but instead exposed to ketone 148 under reductive amination conditions to afford diaminopyran 161 in excellent yield and diastereoselectivity (30:1 dr). Finally, Boc deprotection and crystallization from THF/heptanes furnished omarigliptin in an impressive 45% yield over its nine-step longest linear sequence.
QQ??í?20210205145512.jpg

in vitro

mk-3102 is a competitive, reversible inhibitor of dpp-4 and is more potent than sitagliptin. it is highly selective over all proteases tested, including qpp, fap, pep, dpp8, and dpp9. the compound has weak ion channel activity [1].

in vivo

mk-3102 was evaluated for its ability to improve glucose tolerance in lean mice. when orally administered 1 h prior to dextrose challenge in an oral glucose tolerance test, it significantly reduced blood glucose excursion in a dosedependent manner from 0.01 mg/kg to 0.3 mg/kg [1].

References

[1] biftu t, sinha-roy r, chen p, qian x, feng d, kuethe jt, scapin g, gao yd, yan y, krueger d, bak a, eiermann g, he j, cox j, hicks j, lyons k, he h, salituro g, tong s, patel s, doss g, petrov a, wu j, xu ss, sewall c, zhang x, zhang b, thornberry na, weber ae. omarigliptin (mk-3102): a novel long-acting dpp-4 inhibitor for once-weekly treatment of type 2 diabetes. j med chem. 2014 apr 24;57(8):3205-12.

Properties of Omarigliptin (MK-3102)

Boiling point: 529.4±60.0 °C(Predicted)
Density  1.61±0.1 g/cm3(Predicted)
storage temp.  2-8°C(protect from light)
solubility  insoluble in EtOH; insoluble in H2O; ≥17.15 mg/mL in DMSO
form  solid
pka 9.11±0.60(Predicted)
color  White to off-white
InChI InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1
CAS DataBase Reference 1226781-44-7

Safety information for Omarigliptin (MK-3102)

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H302:Acute toxicity,oral
H315:Skin corrosion/irritation
H319:Serious eye damage/eye irritation
H335:Specific target organ toxicity, single exposure;Respiratory tract irritation
Precautionary Statement Codes P261:Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Computed Descriptors for Omarigliptin (MK-3102)

InChIKey MKMPWKUAHLTIBJ-ISTRZQFTSA-N
SMILES [C@H]1(C2=CC(F)=CC=C2F)OC[C@H](N2CC3=CN(S(C)(=O)=O)N=C3C2)C[C@@H]1N

Related products of tetrahydrofuran

You may like

  • Omarigliptin 95% CAS 1226781-44-7
    Omarigliptin 95% CAS 1226781-44-7
    1226781-44-7
    View Details
  • 1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%
    99903-60-3
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    25408-95-1
    View Details
  • 2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%
    1805639-70-6
    View Details
  • 1784294-80-9 98%
    1784294-80-9 98%
    1784294-80-9
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.